Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial.


Journal

International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108

Informations de publication

Date de publication:
09 2019
Historique:
received: 21 05 2018
accepted: 29 08 2018
revised: 25 07 2018
pubmed: 29 9 2018
medline: 27 5 2020
entrez: 29 9 2018
Statut: ppublish

Résumé

The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown. To assess the effect of Ba8145 and h-k Ba8145 ingestion on anthropometric adiposity biomarkers. Randomized, parallel, double-blind, placebo-controlled trial with abdominally obese individuals. Participants (n = 135) consumed 1 capsule/day containing 10 Ba8145 ingestion decreased waist circumference, waist circumference/height ratio, and Conicity index (P < 0.05) versus its baseline. Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment. Ba8145 decreased the body mass index compared with baseline and placebo group (P < 0.05). The decrease in visceral fat area after Ba8145 treatments reached significance (P < 0.05) only after h-k Ba8145. When analyses by gender were performed, significance remained only for women. Diastolic blood pressure and HOMA index decreased (P < 0.05) after h-k Ba8145. Gut microbiome analyses showed an increase in Akkermansia spp. after Ba8145 treatment, particularly in the live form, which was inversely related to weight (P = 0.003). In abdominally obese individuals, consumption of Ba8145, both as viable and mainly as heat-killed cells, improves anthropometric adiposity biomarkers, particularly in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. Our results support Ba8145 probiotic as a complementary strategy in obesity management.

Sections du résumé

BACKGROUND
The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown.
OBJECTIVE
To assess the effect of Ba8145 and h-k Ba8145 ingestion on anthropometric adiposity biomarkers.
DESIGN
Randomized, parallel, double-blind, placebo-controlled trial with abdominally obese individuals. Participants (n = 135) consumed 1 capsule/day containing 10
RESULTS
Ba8145 ingestion decreased waist circumference, waist circumference/height ratio, and Conicity index (P < 0.05) versus its baseline. Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment. Ba8145 decreased the body mass index compared with baseline and placebo group (P < 0.05). The decrease in visceral fat area after Ba8145 treatments reached significance (P < 0.05) only after h-k Ba8145. When analyses by gender were performed, significance remained only for women. Diastolic blood pressure and HOMA index decreased (P < 0.05) after h-k Ba8145. Gut microbiome analyses showed an increase in Akkermansia spp. after Ba8145 treatment, particularly in the live form, which was inversely related to weight (P = 0.003).
CONCLUSIONS
In abdominally obese individuals, consumption of Ba8145, both as viable and mainly as heat-killed cells, improves anthropometric adiposity biomarkers, particularly in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. Our results support Ba8145 probiotic as a complementary strategy in obesity management.

Identifiants

pubmed: 30262813
doi: 10.1038/s41366-018-0220-0
pii: 10.1038/s41366-018-0220-0
pmc: PMC6760601
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1863-1868

Références

NMR Biomed. 2015 May;28(5):583-90
pubmed: 25808071
J Agric Food Chem. 2016 May 4;64(17):3462-72
pubmed: 27054371
Obes Rev. 2018 Feb;19(2):219-232
pubmed: 29047207
Br J Nutr. 2013 Nov 14;110(9):1696-703
pubmed: 23614897
Nutr J. 2013 Oct 12;12:138
pubmed: 24120179
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
Biosci Microbiota Food Health. 2016;35(4):163-171
pubmed: 27867803
Diabetes. 1998 Jun;47(6):913-7
pubmed: 9604868
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71
pubmed: 23671105
JAMA. 2017 Jul 11;318(2):175-193
pubmed: 28697259
Clin Cardiol. 2015 Sep;38(9):527-34
pubmed: 26418518
Obesity (Silver Spring). 2017 Jan;25(1):30-38
pubmed: 28008750
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
Mucosal Immunol. 2017 Jan;10(1):215-227
pubmed: 27072606
J Nutr Biochem. 2017 Dec;50:16-25
pubmed: 28968517
Benef Microbes. 2017 Oct 13;8(5):739-754
pubmed: 28884589
Eur J Clin Nutr. 2010 Jun;64(6):636-43
pubmed: 20216555
Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96
pubmed: 27353126
Prev Med. 2018 Apr;109:82-97
pubmed: 29291422

Auteurs

Anna Pedret (A)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.

Rosa M Valls (RM)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. rosamaria.valls@urv.cat.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain. rosamaria.valls@urv.cat.

Lorena Calderón-Pérez (L)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.

Elisabet Llauradó (E)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.

Judit Companys (J)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.

Laura Pla-Pagà (L)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.

Ana Moragas (A)

Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.
Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain.
Primary Care Centre Jaume I, Institut Català de la Salut, Tarragona, Spain.

Francisco Martín-Luján (F)

Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.
Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain.
Primary Care Centre El Morell, Institut Català de la Salut, Tarragona, Spain.

Yolanda Ortega (Y)

Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.
Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain.
Primary Care Centre Salou, Institut Català de la Salut, Tarragona, Spain.

Montse Giralt (M)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.

Antoni Caimari (A)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.

Empar Chenoll (E)

Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.

Salvador Genovés (S)

Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.

Patricia Martorell (P)

Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.

Francisco M Codoñer (FM)

Lifesequencing/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.

Daniel Ramón (D)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.

Lluís Arola (L)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Química, Grup de Recerca en Nutrigenòmica, Tarragona, Spain.

Rosa Solà (R)

Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.
Hospital Universitari Sant Joan de Reus, Reus, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH